On the other hand, Momelotinib, a recently approved multi-kinase inhibitor for the treatment of myelofibrosis and anemia, was used in this study at a concentration targeting IKBKE, a TBK1 paralogue (Fig. 6B). Here, TBK1 is linked to anemia (phenotype).